---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-089887"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2024-10-23T23:59:59+00:00"
generated_at: "2026-05-30T11:07:14.904756+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# InMed adds Johns Hopkins Alzheimer's expert Dr. Barry Greenberg to Scientific Advisory Board

## Summary
- Dr. Greenberg is Director of Alzheimer's Disease Translational Center at Johns Hopkins University School of Medicine.
- He has over four decades of Alzheimer's research and held leadership roles at AstraZeneca and Neurochem.
- His expertise will guide InMed's INM-901 drug candidate toward human clinical trials for Alzheimer's disease.
- He serves as Editor-in-Chief of 'Alzheimer's & Dementia: Translational Research and Clinical Interventions'.

## SEC filing metadata
- accession: 0001213900-24-089887
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2024-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390024089887/0001213900-24-089887-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390024089887/ea0218323-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-089887
- JSON: https://secwatch.observer/filing/0001213900-24-089887.json
- Plain text: https://secwatch.observer/filing/0001213900-24-089887.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.